FDA Grants Priority Review for Frontline Zanubrutinib Regimen

Company BeOne Medicines Event Type Regulatory acceptance and Phase 3 topline Modality Small molecule Asset Zanubrutinib (BRUKINSA) plus rituximab Target BTK; CD20 Disease Area Mantle cell lymphoma Summary On November 4, BeOne disclosed FDA acceptance and Priority Review of a supplemental application for zanubrutinib plus…